short engagement, selective CDK9 kinase inh. IV treatment in Ph. I for RR-heme cancers shortened t1/2 from prior preclin. candidate J. Med. Chem., Dec. 11, 2020 AstraZeneca, Cambridge, UK / Boston, MA